Hennion & Walsh Asset Management Inc. Increases Stock Position in ProKidney Corp. (NASDAQ:PROK)

Hennion & Walsh Asset Management Inc. increased its stake in ProKidney Corp. (NASDAQ:PROK - Free Report) by 48.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 844,277 shares of the company's stock after acquiring an additional 275,630 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.29% of ProKidney worth $740,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. ProShare Advisors LLC increased its holdings in ProKidney by 57.3% during the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock valued at $52,000 after purchasing an additional 11,250 shares during the period. Sei Investments Co. purchased a new position in shares of ProKidney during the fourth quarter valued at approximately $69,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of ProKidney during the fourth quarter valued at approximately $88,000. Wells Fargo & Company MN raised its holdings in shares of ProKidney by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 54,098 shares of the company's stock valued at $91,000 after acquiring an additional 18,431 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in ProKidney in the fourth quarter worth $110,000. 51.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ProKidney

In other ProKidney news, insider Control Empresarial De Capital acquired 387,393 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The shares were acquired at an average cost of $0.71 per share, with a total value of $275,049.03. Following the transaction, the insider now owns 73,842,723 shares of the company's stock, valued at $52,428,333.33. The trade was a 0.53% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders purchased a total of 1,787,716 shares of company stock valued at $1,175,419 in the last quarter. 41.49% of the stock is owned by insiders.

ProKidney Stock Up 0.2%

Shares of NASDAQ PROK traded up $0.00 on Monday, reaching $0.98. 514,605 shares of the company's stock traded hands, compared to its average volume of 673,260. The business's 50 day simple moving average is $0.76 and its two-hundred day simple moving average is $1.26. ProKidney Corp. has a 12 month low of $0.46 and a 12 month high of $3.43. The company has a market cap of $286.84 million, a price-to-earnings ratio of -1.78 and a beta of 1.35.

ProKidney (NASDAQ:PROK - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The company had revenue of $0.23 million for the quarter. Analysts forecast that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of ProKidney from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $5.00.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.